Thus, our findings revealed the molecular basis underlying the GPR50 and ADAM17 complex-mediated, ligand-independent modulation of the Notch signaling pathway, which can be exploited in Notch-based HCC therapeutic strategies. Here, ADAM17 is linked to hepatocellular carcinoma.